Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4

Salvatore Zaffina, Eva Piano Mortari, Reparata Rosa Di Prinzio, Marco Cappa, Antonio Novelli, Emanuele Agolini, Massimiliano Raponi, Bruno Dallapiccola, Franco Locatelli, Carlo Federico Perno, Rita Carsetti

Research output: Contribution to journalArticle

Abstract

A 48-year-old patient affected with congenital generalized lipodystrophy type 4 failed to respond to two doses of the BNT162b2 vaccine, consisting of lipid nanoparticle encapsulated mRNA. As the disease is caused by biallelic variants of CAVIN1, a molecule indispensable for lipid endocytosis and regulation, we complemented the vaccination cycle with a single dose of the Ad26.COV2 vaccine. Adenovirus-based vaccine entry is mediated by the interaction with adenovirus receptors and transport occurs in clathrin-coated pits. Ten days after Ad26.COV2 administration, S- and RBD-specific antibodies and high-affinity memory B cells increased significantly to values close to those observed in Health Care Worker controls.
Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalFrontiers in Immunology
Volume13
DOIs
Publication statusPublished - 2022

Keywords

  • case report
  • CAVIN1
  • SARS-CoV-2 vaccine
  • memory B cells
  • congenital generalized lipodystrophy type 4

Fingerprint

Dive into the research topics of 'Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4'. Together they form a unique fingerprint.

Cite this